Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 8, 2006, Pages 1197-1205

  Miyake, Y ^a   Iwasaki, Y ^a   Terada, R ^a   Okamaoto, R ^b   Ikeda, H ^c   Makino, Y ^d   Kobashi, H ^e   Takaguchi, K ^f   Sakaguchi, K ^a   Shiratori, Y ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c KURASHIKI CENTRAL HOSPITAL   (Japan)

^d IWAKUNI NATIONAL HOSPITAL   (Japan)

^e Tsuyama Central Hospital   (Japan)

^f KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CARCINOMA, HEPATOCELLULAR; CHOLAGOGUES AND CHOLERETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISOLONE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 33748897869     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03113.x     Document Type: Article

References (28)

1. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120: 1502-17.
2. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-52.
3. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
4. Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 1944-8.
5. Ryder SD, Koskinas J, Rizzi PM, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology 1995; 22: 718-22.
6. Yamazaki K, Kamiyama T, Shiba S, et al. An aged male patient with autoimmune hepatitis complicated by hepatocellular carcinoma. Intern Med 1999; 38: 422-5.
7. Watanabe M, Moritani M, Hamamoto S, et al. Hepatocellular carcinoma complicating HCV-negative autoimmune hepatitis without corticosteroid therapy. J Clin Gastroenterol 2000; 30: 445-6.
8. Hori K, Fukuda Y, Tomita T, et al. Hepatocellular carcinoma complicating autoimmune hepatitis without either hepatitis C viral infection or corticosteroid therapy. J Gastroenterol 2003; 38: 197-9.
9. Hardee JT, Breth GF, El-Serag HB. Hepatocellular carcinoma associated with autoimmune hepatitis. J Clin Gastroenterol 2003; 37: 271-2.
10. Sakaguchi T, Nakamura S, Suzuki S, et al. Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Surg Today 1995; 25: 838-42.
11. Nishiyama R, Kanai T, Abe J, et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg 2004; 11: 215-9.
12. Miyake Y, Sakaguchi K, Tanaka H, et al. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern Med 2005; 44: 949-53.
13. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-7.
14. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62.
15. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
17. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18: 15-23.
18. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6.
19. Milkiewicz P, Ahmed M, Hathaway M, Elias E. Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Liver 1999; 19: 50-4.
20. Hino T, Kumashiro R, Ide T, et al.; Autoimmune Hepatitis Study Group. Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int J Mol Med 2003; 11: 749-55.
21. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-51.
22. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-5.
23. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 1381-6.
24. Saeian K, Franco J, Komorowski RA, Adams MB. Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. Liver Transpl Surg 1999; 5: 46-9.
25. Cattan S, Wendum D, Chazouilleres O, Schmitz J, Gendre JP. Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Hum Pathol 2000; 31: 874-6.
26. Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 287-90.
27. Borum ML. Unusual development of hepatocellular carcinoma in a patient with Crohn's disease. Dig Dis Sci 2001; 46: 2199-200.
28. Czaja AJ, Freese DK; American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.